Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27957720 | 0.87 | TAAR1 (0.43) | TAAR1P2RX7SMN1; SMN2 | |
| SCHEMBL5826058 | 0.85 | TAAR1 (0.44) | TAAR1GAASMN1; SMN2 | |
| SCHEMBL723742 | 0.79 | TAAR1 (0.48) | TAAR1GAASMN1; SMN2 | |
| SCHEMBL29495163 | 0.79 | TAAR1 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL2703427 | 0.79 | TAAR1 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL29395789 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL5407429 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL2776951 | 0.79 | STIM1 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL145819 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL14405515 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4STIM1ORAI1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909040-A | Preparation method of Elagolix intermediate 2-fluoro-6-trifluoromethylbenzylamine | 南京莱克施德药业有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-03-09 | — | — | US | disclosed |
| WO-2021130776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-07-01 | — | — | WO | disclosed |
| CN-111909040-A | Preparation method of Elagolix intermediate 2-fluoro-6-trifluoromethylbenzylamine | 南京莱克施德药业有限公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| WO-2019112968-A1 | PROCESSES TO PRODUCE ELAGOLIX | WANG PENG (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3404017-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| CN-108698982-A | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | 日产化学工业株式会社 | 2018-10-23 | — | — | CN | disclosed |
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| JP-2006282511-A | 2-TRIFLUOROMETHYL-6-FLUOROBENZAL CHLORIDE AND PRODUCTION METHOD OF IT AND ITS DERIVATIVE | CENTRAL GLASS CO LTD | 2006-10-19 | — | — | JP | disclosed |
| JP-2006213630-A | METHOD FOR PRODUCING 2-TRIFLUOROMETHYL-6-FLUOROBENZALDEHYDE AND ITS DERIVATIVE | CENTRAL GLASS CO LTD | 2006-08-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | SLC6A2 1619/4885SLC6A4 1765/4885STIM1 4586/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | SLC6A2 3724/4885SLC6A4 2837/4885STIM1 3473/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SLC6A2 3724/4885SLC6A4 2837/4885STIM1 3473/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | SLC6A2 1619/4885SLC6A4 1765/4885STIM1 4586/4885 |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | BPNT1, GABRA6, GABRA1 | SLC6A2 2534/4885SLC6A4 2142/4885STIM1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.